Biopharma

Home > Biopharma
  • All
  • Biopharma
  • Life Sciences
December 31, 2020

The combination with Allergan, have created a stronger, more diverse company with robust cash flows, and multiple new growth vehicles for the long term.  The company now have the leading franchise which is demonstrating a strong V-shape recovery, as well as a highly attractive neuroscience portfolio that delivered double-digit growth on a comparable operational basis […]

Read more
November 20, 2020

TECFIDERA situation in the U.S. is clearly a near-term challenge for the company. During Q3FY20, the company began to experience the impact of generic entrants with more than 10 TECFIDERA generics approved and at least six now in the market, and discounted prices of ~90%. Executive Summary Financial Statements – Income Statement and Forecast – […]

Read more
September 30, 2020

The acquisition of Allergan has helped in creating a stronger and more diverse AbbVie. The transaction significantly expands and diversifies AbbVie’s revenue base through leadership positions in immunology and hematological oncology with additional growth franchises in aesthetics and neuroscience. The company experienced growth opportunities in neuroscience with Botox Therapeutics, Vraylar and Ubrelvy. Executive Summary Financial […]

Read more
September 14, 2020

Biogen Inc. and Denali Therapeutics Inc. announced that they have signed a binding agreement to codevelop and co-commercialize Denali’s small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson’s disease. Biogen will also receive rights to opt into two programs and a right of first negotiation for two additional programs, in each case for neurodegenerative […]

Read more
June 22, 2020

Biogen has opened BLA and has started to submit modules, expects to complete the U.S. filing for (Alzheimer’s drug) aducanumab in Q3FY20. It also initiated re-dosing study for aducanumab and higher dose study for SPINRAZA. The company entered collaboration with Sangamo Therapeutics for gene regulation therapies for neurological disease. Executive Summary Financial Statements – Income […]

Read more
June 19, 2019

AbbVie’s revenues declined by 1.3% to $7.83bn in Q1FY19 and increased by 0.4% operationally. The revenues declined due to a decrease in HUMIRA international revenues due to the biosimilar competition. However, HUMIRA revenues from the U.S. increased by 7.1% to $3.2bn in Q1FY19 and will not face biosimilar competition in the U.S. until FY23. Number […]

Read more
June 11, 2019

Biogen delivered strong financial results during the quarter due to the strong operational performance of the MS, SMA, and biosimilars franchises. Total revenues increased by 11% to $3.5bn and adjusted EPS increased by 15% to $6.98 for Q1FY19. Number of Pages – 47 Contents Executive Summary Financial Statements –Income Statement and Forecast –Balance Sheet –Cash […]

Read more
Load more